Zentek Ltd. (NASDAQ:ZTEK – Get Rating) was the target of a large increase in short interest in the month of December. As of December 15th, there was short interest totalling 23,600 shares, an increase of 329.1% from the November 30th total of 5,500 shares. Based on an average daily trading volume, of 23,800 shares, the short-interest ratio is presently 1.0 days. Approximately 0.0% of the shares of the company are short sold.
Zentek Price Performance
Shares of NASDAQ ZTEK traded down $0.02 during trading hours on Wednesday, hitting $1.44. 800 shares of the stock were exchanged, compared to its average volume of 24,348. The company's 50 day moving average is $1.62 and its 200 day moving average is $1.82. Zentek has a one year low of $1.28 and a one year high of $4.35.
Get Zentek alerts:Zentek (NASDAQ:ZTEK – Get Rating) last posted its quarterly earnings data on Monday, November 14th. The company reported ($0.03) earnings per share (EPS) for the quarter. Zentek had a negative return on equity of 405.71% and a negative net margin of 1,617.24%.
Institutional Trading of Zentek
A number of hedge funds have recently bought and sold shares of ZTEK. JPMorgan Chase & Co. bought a new stake in Zentek in the 1st quarter valued at $25,000. Cutter & CO Brokerage Inc. bought a new stake in Zentek in the 2nd quarter valued at $27,000. Cambridge Investment Research Advisors Inc. bought a new stake in Zentek in the 1st quarter valued at $32,000. Bank of Montreal Can bought a new stake in Zentek in the 1st quarter valued at $199,000. Finally, Royal Bank of Canada bought a new stake in Zentek in the 1st quarter valued at $247,000. 0.71% of the stock is owned by institutional investors.About Zentek
(Get Rating)
Zentek Ltd. engages in the research and development of graphene and related nanomaterials in Canada. It owns 100% interest in the Albany Graphite project located in Northern Ontario, Canada. The company develops graphene-based antimicrobial coating under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compound.
Recommended Stories
- Get a free copy of the StockNews.com research report on Zentek (ZTEK)
- The Top Three Stocks Analysts Say To Buy
- Can Dick's Sporting Goods Stock Score Another Win In Q4?
- Why Did Immutep Ltd Stock Soar Recently?
- Yum! Brands Looks Tasty in 2023
- 3 Industrial Stocks to Help Build Your 2023 Watchlist
Receive News & Ratings for Zentek Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentek and related companies with MarketBeat.com's FREE daily email newsletter.